rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

AbCellera Biologics Inc. - Common Shares

ABCL · Nasdaq

Health CareBiotechnologyLeading

ABCL stood above a rising 150-day average in 22 of the last 52 weekly readings, including each of the last 18 weeks. It is 60.1% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
18 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$5.2M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
146 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Michael R. HaydenDirectorbought53,613at $10.6424 Aug 2026filed 24 Aug 2026
John S. MontalbanoDirectorbought10,000at $11.0318 Aug 2026filed 18 Aug 2026
Andrew BoothChief Financial Officerbought37,200at $10.3214 Aug 2026filed 14 Aug 2026
Michael R. HaydenDirectorbought46,387at $10.3712 Aug 2026filed 14 Aug 2026
John S. MontalbanoDirectorbought20,000at $4.7714 May 2026filed 18 May 2026
Andrew BoothChief Financial Officerbought42,600at $3.4227 Feb 2026filed 27 Feb 2026
Thermopylae Holdings Ltd.10% ownerbought38,000at $3.4427 Feb 2026filed 2 Mar 2026
Thermopylae Holdings Ltd.10% ownerbought177,457at $3.2726 Feb 2026filed 27 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders146+16 on the quarter
New · exited39 · 23
Reported value$886.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BAKER BROS. ADVISORS LPadded · filed 14 Aug 202633,012,138$259.1M+2,736,200+9.0%
Capital World Investorsadded · filed 12 Aug 202613,588,349$106.7M+227,253+1.7%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 202610,437,431$81.9M-124,634−1.2%
TD Waterhouse Canada Inc.added · filed 27 Jul 20269,568,149$72.6M+3,4900.0%
BANK OF AMERICA CORPadded · filed 14 Aug 20266,141,539$48.2M+3,141,603+104.7%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCreduced · filed 13 Aug 20264,317,206$33.9M-3,258,270−43.0%
ArrowMark Colorado Holdings LLCunchanged · filed 13 Aug 20264,105,095$32.2M00.0%
BlackRock, Inc.reduced · filed 7 Aug 20263,805,309$29.9M-234,927−5.8%
Driehaus Capital Management LLCreduced · filed 14 Aug 20262,864,729$22.5M-1,160,050−28.8%
TUDOR INVESTMENT CORP ET ALreduced · filed 14 Aug 20262,063,191$16.2M-210,298−9.3%
31 Mar 2023 – 30 Jun 2026
117131145Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Michael R. Hayden Company insiderDirector · last 24 Aug 20265 · 1
John S. Montalbano Company insiderDirector · last 18 Aug 202611 · 0
Andrew Booth Company insiderChief Financial Officer · last 14 Aug 20265 · 1
Lynn Seely Company insiderDirector · last 1 Jul 20260 · 0
Victor Sandor Company insiderDirector · last 1 Jul 20260 · 0
Stephen Quake Company insiderDirector · last 11 Jun 20260 · 0
Thermopylae Holdings Ltd. Company insider10% owner · last 27 Feb 202613 · 1
Carl L. G. Hansen Company insiderChief Executive Officer · last 1 Jan 20260 · 1
Tryn Stimart Company insiderChief Legal Officer · last 1 Jan 20261 · 1
Veronique Lecault Company insiderChief Technology Officer · last 1 Jan 20264 · 1
Andrew Lo Company insiderDirector · last 12 Jun 20251 · 0
Ester Falconer Company insiderChief Technology Officer · last 1 Sep 20210 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-289%
Free cash flow marginFY 2025 · to 31 Dec 2025-232%
Return on capital employedFY 2025 · to 31 Dec 2025-16.8%
Research spendFY 2025 · to 31 Dec 2025249%
Share count trendFY 2025 · to 19 Feb 20260.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$61.8M
Free cash flowFY 2025 · to 31 Dec 2025−$174.1M

Analyst forecasts

No analyst forecasts yet.